(Access to Coverage of Tobacco Treatment In Our Nation)
Partnership for Prevention
Shaping Policies | Improving Health
Chantix Psychiatric Side Effects Not Seen in FDA Studies
October 26, 2011 Two studies sponsored by the FDA failed to find a link between Pfizer’s smoking cessation drug Chantix and psychiatric problems, such as increased incidents of suicide and violent behavior. The FDA issued a Chantix drug safety communication on October 24, indicating that two epidemiological studies failed to find an increase in the risk of dangerous psychiatric side effects with Chantix use. The findings run counter to a number of other reports that suggest Chantix side effects increase the risk of suicidal behavior, sudden outbursts of violence, depression, and other psychological problems.
For More Information:
http://www.aboutlawsuits.com/fda-chantix-study-results-22082/
Join the Network!
Complete the form below to subscribe to the ActionToQuit Network. Stay connected and informed - receive regular updates on the latest in tobacco control policy.
In The News RSS
- May 17, 2012
Youth Smoking Falls as Taxes Make Cigarettes Too Costly
Read the full story - May 17, 2012
Behind the Scenes in the Racketeering Case Against the Tobacco Industry
Read the full story - May 16, 2012
Secondhand Smoke May Harm Heart Function
Read the full story - May 16, 2012
Commissioners Attempt to Ban Flavored Tobacco
Read the full story
All Content © ActionToQuit. All Rights Reserved